Status:
TERMINATED
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
Lead Sponsor:
Fred Lublin
Collaborating Sponsors:
National Multiple Sclerosis Society
Pfizer
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
This clinical trial compares the relative efficacy of treating acute exacerbations of relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV) methylprednisolone. This ...
Detailed Description
Intravenous methylprednisolone has been the standard of care for treating acute MS flares. However, the IV administration is cumbersome, inconvenient and expensive. A true comparison of these differen...
Eligibility Criteria
Inclusion
- Between the ages of 18 and 50 years, inclusive.
- Acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms, and with signs referable to the symptoms; in the absence of a fever or active infection.
- Diagnosis of a relapsing form of multiple sclerosis before randomization as determined by Poser or McDonald Criteria.
- Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.
- Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.
- New objective clinical finding other than a sensory exacerbation, or bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.
- Subjects may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids should discontinue immunomodulatory treatment.
- Understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care.
Exclusion
- Any patients treated with systemic corticosteroid use within one month of the index episode at screening.
- Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, IVIg) or plasmapheresis.
- Any patient who is pregnant or breastfeeding.
- Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).
- Peripheral or cranial neuropathy as sole problem of acute episode.
- History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy.
- Primary Progressive Multiple Sclerosis (PPMS).
- Previous participation in this study.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00418145
Start Date
September 1 2003
End Date
October 1 2013
Last Update
May 18 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Medicine and Dentistry of New Jersey
New Brunswick, New Jersey, United States, 08901
2
Maimonides Medical Center
Brooklyn, New York, United States, 11219
3
The Jacobs Neurological Institute
Buffalo, New York, United States, 14203
4
Hospital For Joint Diseases
New York, New York, United States, 10003